Patents by Inventor Sandra Jablonski

Sandra Jablonski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATING FIBROSIS WITH A CCK RECEPTOR INHIBITOR
    Publication number: 20240216391
    Abstract: Provided herein are methods for treating fibrosis (e.g. pancreatic fibrosis) in a subject. Some methods comprise administering to a subject having pancreatic fibrosis an effective amount of a CCK receptor inhibitor.
    Type: Application
    Filed: February 9, 2024
    Publication date: July 4, 2024
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: Jill P. SMITH, Louis WEINER, Sandra JABLONSKI, Sandeep NADELLA, Shangzi WANG
  • TREATING CANCER WITH A CCK RECEPTOR INHIBITOR AND AN IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20220257609
    Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.
    Type: Application
    Filed: February 23, 2022
    Publication date: August 18, 2022
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: Jill P. SMITH, Louis WEINER, Sandra JABLONSKI, Sandeep NADELLA, Shangzi WANG
  • Treating cancer with a CCK receptor inhibitor and an immune checkpoint inhibitor
    Patent number: 11278551
    Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 22, 2022
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Jill P. Smith, Louis Weiner, Sandra Jablonski, Sandeep Nadella, Shangzi Wang
  • TREATING CANCER WITH A CCK RECEPTOR INHIBITOR AND AN IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20200383996
    Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. Also provided are methods for increasing sensitivity of a (CCK) receptor-expressing cancerous tumor in a subject to immunotherapy.
    Type: Application
    Filed: March 15, 2018
    Publication date: December 10, 2020
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: Jill P. Smith, Louis Weiner, Sandra Jablonski, Sandeep Nadella, Shangzi Wang
  • Genes encoding proteins involved in mitotic checkpoint control and methods of use thereof
    Patent number: 6593098
    Abstract: Novel human BUB genes and their encoded proteins are provided herein. The kinases encoded by the disclosed BUB1A and BUB1B genes play a pivotal role in mitotic checkpoint control. BUB3 is a substrate of these kinases, BUB genes and their encoded proteins provide valuable therapeutic targets for the design of anti-proliferative agents which inhibit the aberrant cellular proliferation observed in tumor cells.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: July 15, 2003
    Assignee: Fox Chase Cancer Center
    Inventors: Timothy Yen, Gordon Chan, Sandra Jablonski